Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology
Avoids 4-1BB/OX-40 Toxicity Issues
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
You may also be interested in...
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.
In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo’s GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.